X-Linked Hypophosphatemia: A New Era in Management.

Abstract

X-linked hypophosphatemia (XLH) is a rare, hereditary, progressive musculoskeletal disease that often causes pain and short stature, as well as decreased physical function, mobility, and quality of life. Hypophosphatemia in XLH is caused by loss of function mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene, resulting in excess levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), which leads to renal phosphate wasting and decreased serum 1,25-dihydroxyvitamin D production. Historically, treatment options were limited to oral phosphate and active vitamin D analogues (conventional management) dosed several times daily in an attempt to improve skeletal mineralization by increasing serum phosphorus. The recent approval of burosumab, a fully human monoclonal antibody to FGF23, has provided a new, targeted treatment option for patients with XLH. This review summarizes our current understanding of XLH, the safety and efficacy of conventional management and burosumab, existing recommendations for managing patients, and unanswered questions in the field.

• Authors: Kathryn Dahir, Mary Scott Roberts, Stan Krolczyk, Jill H Simmons
• Journal: Journal of the Endocrine Society (J Endocr Soc) Vol. 4 Issue 12 Pg. bvaa151 (Dec 01 2020) ISSN: 2472-1972 [Electronic] United States
• PMID: 33204932 (Publication Type: Journal Article, Review)
• Copyright: © The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.